CoChat

Live biotherapeutic products: the importance of a defined regulatory framework

Open access
Cordaillat-Simmons, Magali, Rouanet, Alice, Pot, Bruno · 2020 · Experimental & Molecular Medicine

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Probiotics have been defined as “Live microorganisms that when administered in adequate amounts confer a health benefit on the host”. This definition covers a wide range of applications, target populations and (combinations of) microorganisms. Improved knowledge on the importance of the microbiota in terms of health and disease has further diversified the potential scope of a probiotic intervention, whether intended to reach the market as a food, a food supplement or a drug, depending on the intended use. However, the increased interest in the clinical application of probiotics may require specific attention given their administration in a diseased population. In addition to safety, the impact of the type of product, in terms of quality, production method and, e.g., the acceptance of side effects, is now part of the current regulatory constraints for developers. In the European Union, foods are regulated by the European Food Safety Authority and drugs by the European Medicines Agency; in the United States, the Food and Drug Administration (FDA) deals with both categories. More recently, the FDA has defined a new “live biotherapeutic products” (LBP) category, clarifying pharmaceutical expectations. Since 2019, the quality requirements for this category of drug products have also been clarified by the European Pharmacopoeia (Ph. Eur.). Similar to all products intended to prevent or treat diseases, LBPs will have to be registered as medicinal products to reach the market in the US and in Europe. In this area, regulatory authorities and the pharmaceutical industry will routinely use guidelines of the “International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use” (ICH). Although ICH guidelines are not legally binding, they provide very important recommendations, recognized by almost all drug authorities in the world. In this review, we discuss some aspects of this regulatory framework, especially focusing on products with an intended use in a diseased or vulnerable target population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-020-0437-6

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clarification of the terminology and corresponding regulatory status.
Fig. 1 Clarification of the terminology and corresponding regulatory status.CC BY · PubMed Central
Fig. 2 Different regulatory frameworks in ICH7 guidelines based on the nature of the medicinal product.
Fig. 2 Different regulatory frameworks in ICH7 guidelines based on the nature of the medicinal product.CC BY · PubMed Central
Fig. 3 EU legislative framework relative to biological medicinal products.
Fig. 3 EU legislative framework relative to biological medicinal products.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 30 references

Research works printed but not linked: 4

  1. ICH. Guideline M3(R2) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. https://doi.org/10.1163/ej.9789004163300.i-1081.897 (ICH, 2010). · DOI · Paper page
  2. ICH. Guideline Q11 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. https://doi.org/10.1163/ej.9789004163300.i-1081.897 (ICH, 2010). · DOI · Paper page
  3. ICH. Guideline Q8 (R2) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. https://doi.org/10.1163/ej.9789004163300.i-1081.897 (ICH, 2010). · DOI · Paper page
  4. ICH. Guideline S6(R1)International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. https://doi.org/10.1163/ej.9789004163300.i-1081.897 (ICH, 2010). · DOI · Paper page

Cited by

See all 330

Metadata

Authors
Cordaillat-Simmons, M., Rouanet, A., & Pot, B.
Affiliations
Vrije Universiteit Brussel (BE)
Corresponding author
Pot, Bruno
Venue
Experimental & Molecular Medicine
Published
2020-09
Volume
52
Issue
9
Pages
1397-1406
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W3083900288
Cited by
328
References
29
Citations by year
2026: 99 · 2025: 85 · 2024: 53 · 2023: 36 · 2022: 32 · 2021: 20 · 2020: 3
FWCI
1.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
live biotherapeutic products, probiotics, regulatory framework, ICH guidelines, non-functional requirements, European Pharmacopoeia, FDA, European Medicines Agency, EFSA, microbiota, drug registration, vulnerable populations
MeSH terms
Drug Development, Animals, Biological Products, Biological Therapy, Humans, Legislation, Drug, Guidelines as Topic, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Live biotherapeutic products: the importance of a defined regulatory framework. https://app.cochat.ai/papers/10.1038/s12276-020-0437-6
The paper
Cordaillat-Simmons, M., Rouanet, A., & Pot, B. (2020). Live biotherapeutic products: the importance of a defined regulatory framework. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-020-0437-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.